A registration-directed phase II trial of AFM13, a CD30/CD16A bispecific antibody, in CD30-positive PTCL or transformed MF, has completed enrollment (NCT04101331) (93). This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.